High blood pressure (BP4140/90 mmHg) is present in up to 80% of patients in the period immediately after stroke, whether of ischaemic or haemorrhagic type. Several mechanisms may be causative (1) including preexisting hypertension, the stress of hospitalisation, raised intracranial pressure and activation of neuro-endocrine systems. BP declines to prestroke levels over the first week in most people.
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Analyses in both small and large studies (2) reveal that high BP is associated independently with poor outcome, both early death and late death/dependency. Mechanisms for this relationship in ischaemic stroke include an increased risk of early recurrence and severe cerebral oedema (2) but not increased haemorrhagic transformation. In primary intracerebral haemorrhage (PICH), high BP possibly contributes to haematoma expansion (3), although this relationship may be artificial because it is confounded by time to presentation.
Cerebral autoregulation, which maintains cerebral blood flow over a wide range of BP levels, is dysfunctional following stroke so that perfusion may become dependent on BP. In this context, lowering BP might reduce the cerebral blood flow and worsen the outcome. As a result, clinical equipoise results from these disparate findings; epidemiology suggests that high BP should be lowered while pathophysiology argues that it should not be. Unfortunately, such equipoise has been present for more than 25 years (4), and definitive evidence is yet to materialise.
Several small trials have assessed antihypertensive agents in patients with acute stroke, although it must be noted that these studies were often testing a neuroprotection hypothesis. Overall, calcium channel blockers (CCBs) did not alter outcome after ischaemic stroke (29 trials, 7665 patients) (5); however, some, especially those testing intravenous formulations, reported hazard, e.g. INWEST.(6) Although there are less data for b-receptor antagonists, the BEST trial showed a trend towards increased death and disability in the treatment group. (7) In contrast, trials of angiotensin receptor antagonists (ARAs) appear more hopeful; oral candesartan reduced combined cerebral and cardiac vascular events in 339 patients with ischaemic stroke (although it had no effect on death/disability, the primary outcome) (8) . Oral losartan (another ARA) reduced BP without altering CBF in 24 patients with sub-acute stroke (9) . Similarly, transdermal glyceryl trinitrate (GTN) (a nitric oxide donor) lowered BP while maintaining global and regional CBF in 18 patients (10) ; the absence of antiplatelet effects with GTN means that it can be used in patients with intracerebral haemorrhage (ICH).
Several large trials are ongoing and it is to be hoped that these can provide definitive evidence. Both COSSACS and ENOS are assessing whether prestroke antihypertensive agents should be continued or stopped temporarily (11, 12) . ENOS and SCAST (http://www.scast.no/) are assessing the effect of lowering BP with GTN (12) or candesartan (respectively); these trials include patients with either ischaemic stroke or ICH. In contrast, the INTERACT trial is focusing on the hyperacute treatment of patients with PICH.
Until further evidence becomes available, clinical practice is driven by expert opinion as published in guidelines. Patients with severe concomitant vascular complications such as encephalopathy, cardiac ischaemia or failure or aortic dissection should have their BP lowered as part of the management of these concomitant conditions. Unfortunately, the remaining parts of guidelines vary considerably, ranging from 'do nothing', through 'lower BP by up to 20%', to 'lower systolic BP to below 140 mmHg' . Preferred drugs include labetalol, CCBs, GTN and sodium nitroprusside. In general, the guidelines recommend more active intervention in patients with PICH than ischaemic stroke.
However, the published guidelines are not always logical. First, lowering BP to a given level without taking account of the starting point means that some patients may have their BP lowered by a small amount (e.g. reduction in systolic BP from 155 to 140 mmHg is 10%) while others will be exposed to large reductions (from 200 to 140 mmHg is 30%). Even normal subjects would struggle to tolerate this latter degree of reduction and the risk in stroke patients is that cerebral perfusion will be reduced, particularly if BP elevation was long standing with a resulting right shift of the autoregulation curve. Results from the INWEST trial support this assertion, with patients having BP reductions of 420% being more likely to have a poor outcome than those whose BP declined by o20% (6) .
Second, several antihypertensive classes of drugs have potentially undesirable effects that might worsen the outcome. (13) or induce cerebral steal. b-receptor antagonists such as labetalol and atenolol are negative inotropes that might also worsen perfusion, although trials assessing their pathophysiological effects in stroke have yet to be reported. Several classes, including CCBs and nitroprusside, have anti-platelet effects (14, 15) and these agents cannot be recommended in PICH unless explicit evidence becomes available that their antihaemostatic activity is not clinically relevant. It has also been speculated that cerebral vasodilators such as nitrates should be avoided because they will tend to increase intracranial pressure although one small trial did not find this effect with GTN (10) .
Third, the formulation and route of administration needs to be considered. As highlighted already, intravenous preparations require use in a high-dependency clinical environment and can cause profound BP lowering, which was detrimental in at least one trial (6) .
Oral antihypertensives have limitations: they are difficult to administer if patients are dysphagic because enteral access is unreliable during the acute phase of stroke; slow-release preparations cannot be administered by nasogastric tube because the required crushing destroys their delayed action; and their action cannot easily be reversed. Sublingual CCBs should always be avoided because they induce precipitous and only short-term declines in BP.
So what should clinicians do in the majority of patients with acute stroke who have a high BP? In the absence of definitive data, they should enrol the patient in one of the ongoing randomised-controlled trials. We rarely intervene without a trial but if the sustained systolic BP4220 mmHg, our preferred choice is transdermal GTN because it can be used in both ischaemic stroke and PICH, has a moderate speed of onset and effect on BP (B5-15%) and can be given whether or not dysphagia is present. However, whether GTN improves outcome, as opposed to just lowering BP, remains to be established (12) . CCBs, labetalol, and nitroprusside are recommended in guidelines but again their use is not based on randomised evidence.
